SCA
ALNY icon

Stonebridge Capital Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Stonebridge Capital Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-6
Closed -$1K – 971
2022
Q3 		$1K Buy
+6
New +$1.14K ﹤0.01% 854

Other funds holding ALNY

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Stonebridge Capital Advisors's ALNY Position: Q4 2022 in Review

Stonebridge Capital Advisors sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2022, closing a stake of 6 shares — an estimated $1K sold.

Stonebridge Capital Advisors first reported a position in ALNY in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 487 funds tracked by Wall St. Rank hold ALNY as of Q4 2022.

  • Stonebridge Capital Advisors reported no remaining Alnylam Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Stonebridge Capital Advisors sold 6 Alnylam Pharmaceuticals shares in Q4 2022, an estimated $1K.
  • Stonebridge Capital Advisors first reported a position in Alnylam Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Stonebridge Capital Advisors's Alnylam Pharmaceuticals position peaked at $1K in Q3 2022.
  • 487 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2022.

Based on Stonebridge Capital Advisors's 13F filing for Q4 2022, filed 14 Feb 2023.